600
Participants
Start Date
November 15, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2027
Pharmacogenomic test
The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
Central Support Services, Aurora
Collaborators (1)
OneOme, LLC
INDUSTRY
Kaiser Permanente
OTHER